Peptidyl-urea based inhibitors of soluble epoxide hydrolases

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 20, 2006, Pages 5439-5444

  Morisseau, Christophe ^a   Newman, John W ^a   Tsai, Hsing Ju ^a   Baecker, Preston A ^b   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Arete Therapeutics Inc   (United States)

Author keywords

Cardiovascular diseases; Soluble epoxide hydrolase inhibitors

Indexed keywords

ADAMANTYL UREA; AMANTADINE DERIVATIVE; AMINO ACID DERIVATIVE; CYCLOHEXANE DERIVATIVE; CYCLOHEXYL UREA; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; PEPTIDYL UREA DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYDROPHOBICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; MICE; MOLECULAR STRUCTURE; PEPTIDES; RATS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

CANIS FAMILIARIS;

EID: 33748302000     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.073     Document Type: Article

References (31)

1. Morisseau C., and Hammock B.D. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 311
2. Harder D.R., Campbell W.B., and Roman R.J. J. Vasc. Res. 32 (1995) 79
3. Campbell W.B., Gebremedhin D., Pratt P.F., and Harder D.R. Circ. Res. 78 (1996) 415
4. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., and Liao J.K. Science 285 (1999) 1276
5. Newman J.W., Morisseau C., and Hammock B.D. Prog. Lipid Res. 44 (2005) 1
6. Spector A.A., Fang X., Snyder G.D., and Weintraub N.L. Prog. Lipid Res. 43 (2004) 55
7. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A 96 (1999) 8849
8. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Circ. Res. 87 (2000) 992
9. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Hypertension 39 (2002) 690
10. Jung O., Brandes R.P., Kim I., Schweda F., Schmidt R., Hammock B.D., Busse R., and Fleming I. Hypertension 45 (2005) 759
11. Loch, D.; Hoey, A.; Morisseau, C.; Hammock, B. D.; Brown, L; Cell. Biochem. Biophys. in press.
12. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A 102 (2005) 9772
13. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A 102 (2005) 2186
14. Zhao X., Yamamoto T., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., and Imig J.D. J. Am. Soc. Nephrol. 15 (2004) 1244
15. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.H., Watanabe T., and Hammock B.D. Hypertension 46 (2005) 975
16. Argiriadi M.A., Morisseau C., Goodrow M.H., Dowdy D.L., Hammock B.D., and Christianson D.W. J. Biol. Chem. 275 (2000) 15265
17. Gomez G.A., Morisseau C., Hammock B.D., and Christianson D.W. Biochemistry 43 (2004) 4716
18. Morisseau C., Goodrow M.H., Newman J.W., Wheelock C.E., Dowdy D.L., and Hammock B.D. Biochem. Pharmacol. 63 (2002) 1599
19. Kim I.H., Morisseau C., Watanabe T., and Hammock B.D. J. Med. Chem. 47 (2004) 2110
20. Kim I.H., Heirtzler F.R., Morisseau C., Nishi K., Tsai H.J., and Hammock B.D. J. Med. Chem. 48 (2005) 3621
21. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Deliv. Rev. 46 (2001) 3
22. Grant D.E., Storms D.H., and Hammock B.D. J. Biol. Chem. 268 (1993) 17628
23. Beetham J.K., Tian T., and Hammock B.D. Arch. Biochem. Biophys. 305 (1993) 197
24. Wixtrom R.N., Silva M.H., and Hammock B.D. Anal. Biochem. 169 (1988) 71
25. Dietze E.C., Kuwano E., and Hammock B.D. Anal. Biochem. 216 (1994) 176
26. Gomez G.A., Morisseau C., Hammock B.D., and Christianson D.W. Protein Sci. 15 (2006) 58
27. Meyer E.A., Castellano R.K., and Diederich F. Angew. Chem. Int. Ed. 42 (2003) 1210
28. 3′-5′) ppm.
29. 3″-5″) ppm.
30. Selected soluble epoxide hydrolase inhibitors were prepared at 6 mg/mL in triglycerides. Each dog was dosed orally with three different inhibitors per experiment (dose = 0.3 mg/kg per inhibitor). Plasma samples were collected at 0, 15, 30, 60, 120, 180, 240, 300, 360, 480, and 1440 min, and analyzed by LC/MS/MS (Quattro Premier; Micromass, MA). The pharmacokinetic parameters were calculated with WinNonlin 5.0 (Pharsight, CA).
31. Oh D.M., Han H.K., Williamson R.M., Bigge C.F., Amidon G.L., Stewart B.H., and Surendran N. J. Pharm. Sci. 12 (2002) 2579